Search Results - "Decloedt, J"

Neoadjuvant Chemotherapy or Primary Debulking Surgery in Advanced Ovarian Carcinoma: A Retrospective Analysis of 285 Patients by Vergote, I., De Wever, I., Tjalma, W., Van Gramberen, M., Decloedt, J., van Dam, P.

“…Objective.This study was aimed at comparison of neoadjuvant chemotherapy with primary debulking surgery in advanced ovarian carcinoma. Methods.Retrospective…”
Get full text

BREAST CANCER PREVENTION: LIFESTYLE CHANGES AND CHEMOPREVENTION by Lambrechts, S, Decloedt, J, Neven, P

“…Susceptibility to breast cancer is caused by a combination of genetic and environmental factors. Research is exploring which factors influence breast cancer…”
Get full text

Neoadjuvant chemotherapy versus primary debulking surgery in advanced ovarian cancer by Vergote, I B, De Wever, I, Decloedt, J, Tjalma, W, Van Gramberen, M, van Dam, P

“…Primary surgical cytoreduction followed by chemotherapy usually is the preferred management of advanced (stage III or IV) ovarian cancer. The presence of…”
Get more information

The Feasibility of Open Laparoscopy in Gynecologic–Oncologic Patients by Decloedt, J., Berteloot, P., Vergote, I.

“…Gynecologic–oncologic patients are at increased risk for complications with closed laparoscopy. Open laparoscopy eliminates the steps of blind insufflation and…”
Get full text

Laparoscopy in gynaecologic oncology: a review by Decloedt, J., Vergote, I.

Get full text

Abstract P3-07-46: CYPTAM-BRUT 3: Endometrial thickness cannot be used as a marker for tamoxifen metabolization in postmenopausal breast cancer patients by Poppe, A, Dieudonné, A-S, Lintermans, A, Laenen, A, Blomme, C, Lambrechts, D, Wildiers, H, Christiaens, M-R, Timmerman, D, Van Calster, B, Vereecke, C, Vandeputte, G, Fontaine, C, Decloedt, J, Berteloot, P, Depypere, H, Joerger, M, Dezentjé, V, Neven, P

“…Abstract Background: Tamoxifen is commonly used for the treatment of all stages of estrogen receptor (ER) positive breast cancer (BC), the largest group of BC…”
Get full text

Abstract OT3-2-04: Prospective multicenter study evaluating the effect of impaired tamoxifen metabolization on efficacy in breast cancer patients receiving tamoxifen in the neo-adjuvant or metastatic setting - The CYPTAM-BRUT 2 trial by Van Asten, K, Dieudonné, A-S, Lintermans, A, Blomme, C, Brouckaert, O, Lambrechts, D, Wildiers, H, Christiaens, M-R, Timmerman, D, Van Calster, B, Decloedt, J, Berteloot, P, Verhoeven, D, Joerger, M, Zaman, K, Dezentjé, V, Neven, P

“…Abstract Background Tamoxifen is often used for the prevention and treatment of hormone receptor positive breast cancer. It is a prodrug which is metabolized…”
Get full text

Abstract OT2-2-02: Prospective multicentre study evaluating the effect of impaired tamoxifen metabolization on efficacy in breast cancer patients receiving tamoxifen in the neo-adjuvant or metastatic setting - The CYPTAM-BRUT 2 trial by Lintermans, A, Dieudonné, A-S, Blomme, C, Lambrechts, D, Wildiers, H, Christiaens, M-R, Timmerman, D, Van Calster, B, Decloedt, J, Berteloot, P, Joerger, M, Zaman, K, Dezentjé, V, Neven, P

“…Abstract Background: Tamoxifen is often used for the prevention and treatment of hormone receptor positive breast cancer. It is metabolized in the liver…”
Get full text

Trocar implantation metastasis after laparoscopy in patients with advanced ovarian cancer: Can the risk be reduced? by van Dam, Peter A., DeCloedt a, Jan, Tjalma, Wiebren A.A., Buytaert, Philippe, Becquart, Dominique, Vergote, Ignace B.

“…Objective: The purpose of this study was to determine risk factors for trocar implantation metastasis after diagnostic laparoscopy in patients with primary or…”
Get full text

Interval debulking surgery: An alternative for primary surgical debulking? by Vergote, Ignace, De Wever, Ivo, Tjalma, Wiebren, Van Gramberen, Marleen, Decloedt, Jan, Van Dam, Peter

“…Retrospective analyses suggest that a subgroup of patients with Stage III and IV ovarian carcinoma can be treated with neo‐adjuvant chemotherapy followed by…”
Get full text